| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 15 | 2023 | 51 | 4.710 |
Why?
|
| Clinical Trials as Topic | 8 | 2023 | 440 | 2.360 |
Why?
|
| Quality Assurance, Health Care | 6 | 2021 | 250 | 2.280 |
Why?
|
| Neoplasms | 14 | 2024 | 1232 | 2.200 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2024 | 55 | 1.860 |
Why?
|
| Hodgkin Disease | 10 | 2019 | 55 | 1.750 |
Why?
|
| Radiosurgery | 3 | 2021 | 61 | 1.650 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2024 | 31 | 1.590 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 244 | 1.260 |
Why?
|
| Radiotherapy, Conformal | 4 | 2023 | 19 | 1.170 |
Why?
|
| Radiation Injuries | 5 | 2019 | 62 | 1.160 |
Why?
|
| Clinical Protocols | 5 | 2018 | 136 | 1.130 |
Why?
|
| Radiotherapy | 4 | 2019 | 61 | 1.120 |
Why?
|
| Prostatic Neoplasms | 6 | 2018 | 339 | 1.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2021 | 402 | 1.030 |
Why?
|
| Lung Neoplasms | 8 | 2022 | 584 | 1.020 |
Why?
|
| Radiation Tolerance | 4 | 2024 | 49 | 0.960 |
Why?
|
| Proton Therapy | 3 | 2021 | 8 | 0.930 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 125 | 0.840 |
Why?
|
| Radiotherapy Dosage | 12 | 2024 | 81 | 0.760 |
Why?
|
| Insurance Carriers | 1 | 2021 | 7 | 0.750 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2018 | 33 | 0.740 |
Why?
|
| Hematuria | 1 | 2021 | 20 | 0.730 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 15 | 0.720 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 28 | 0.710 |
Why?
|
| Nephrectomy | 1 | 2021 | 66 | 0.710 |
Why?
|
| Developing Countries | 2 | 2017 | 86 | 0.670 |
Why?
|
| Humans | 66 | 2024 | 59440 | 0.660 |
Why?
|
| Palliative Care | 1 | 2021 | 214 | 0.620 |
Why?
|
| Tissue Expansion Devices | 3 | 2017 | 17 | 0.620 |
Why?
|
| International Cooperation | 3 | 2018 | 84 | 0.620 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 14 | 0.610 |
Why?
|
| Child | 20 | 2024 | 4194 | 0.610 |
Why?
|
| Lymphoma | 1 | 2019 | 99 | 0.590 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 167 | 0.590 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 276 | 0.550 |
Why?
|
| Breast Neoplasms | 6 | 2015 | 1118 | 0.550 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2022 | 147 | 0.530 |
Why?
|
| Radiodermatitis | 2 | 2016 | 11 | 0.520 |
Why?
|
| Heart | 1 | 2018 | 274 | 0.520 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1482 | 0.460 |
Why?
|
| Film Dosimetry | 1 | 2014 | 9 | 0.460 |
Why?
|
| Lung | 2 | 2021 | 920 | 0.450 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 302 | 0.450 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 13 | 0.440 |
Why?
|
| Diaphragm | 1 | 2014 | 21 | 0.440 |
Why?
|
| Tissue Expansion | 3 | 2020 | 24 | 0.420 |
Why?
|
| Androgens | 2 | 2010 | 47 | 0.390 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 1368 | 0.390 |
Why?
|
| Perfusion Imaging | 1 | 2012 | 19 | 0.380 |
Why?
|
| Neuropilin-2 | 2 | 2024 | 39 | 0.380 |
Why?
|
| Oximetry | 1 | 2012 | 48 | 0.380 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 59 | 0.370 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 207 | 0.360 |
Why?
|
| Male | 30 | 2024 | 27775 | 0.340 |
Why?
|
| Whole-Body Irradiation | 3 | 2024 | 33 | 0.330 |
Why?
|
| Quality of Health Care | 1 | 2014 | 514 | 0.330 |
Why?
|
| Female | 31 | 2024 | 30757 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 323 | 0.320 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 5 | 0.310 |
Why?
|
| Anilides | 1 | 2008 | 17 | 0.310 |
Why?
|
| Integrins | 3 | 2016 | 106 | 0.310 |
Why?
|
| Young Adult | 10 | 2021 | 4273 | 0.310 |
Why?
|
| Nitriles | 1 | 2008 | 62 | 0.300 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2020 | 9 | 0.300 |
Why?
|
| Adolescent | 11 | 2021 | 5844 | 0.290 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 23 | 0.270 |
Why?
|
| Prognosis | 4 | 2021 | 1597 | 0.270 |
Why?
|
| Child, Preschool | 9 | 2021 | 1794 | 0.270 |
Why?
|
| Chemoradiotherapy | 4 | 2020 | 49 | 0.260 |
Why?
|
| Medical Oncology | 2 | 2023 | 57 | 0.260 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 27 | 0.250 |
Why?
|
| Terminology as Topic | 2 | 2017 | 133 | 0.250 |
Why?
|
| Phantoms, Imaging | 2 | 2018 | 217 | 0.240 |
Why?
|
| Ammonia | 1 | 2024 | 15 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 237 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2016 | 66 | 0.230 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 22 | 0.230 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 133 | 0.230 |
Why?
|
| Nitric Oxide | 1 | 2024 | 146 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 1512 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 628 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 196 | 0.210 |
Why?
|
| Oxidative Stress | 1 | 2024 | 279 | 0.200 |
Why?
|
| Aged | 13 | 2021 | 13426 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 197 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 2339 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 448 | 0.190 |
Why?
|
| United States | 7 | 2020 | 7430 | 0.190 |
Why?
|
| Sarcoma | 2 | 2018 | 36 | 0.190 |
Why?
|
| Medulloblastoma | 1 | 2021 | 11 | 0.190 |
Why?
|
| Adult | 12 | 2021 | 15695 | 0.180 |
Why?
|
| Cisplatin | 6 | 2018 | 119 | 0.180 |
Why?
|
| Insurance Coverage | 1 | 2021 | 99 | 0.180 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 7 | 0.180 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2020 | 8 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2021 | 144 | 0.170 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 200 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 45 | 0.170 |
Why?
|
| Meningeal Neoplasms | 2 | 2015 | 58 | 0.170 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 14 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 65 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2021 | 3069 | 0.160 |
Why?
|
| Doxorubicin | 6 | 2020 | 97 | 0.160 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 46 | 0.160 |
Why?
|
| Down-Regulation | 2 | 2018 | 307 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 181 | 0.160 |
Why?
|
| Rad51 Recombinase | 1 | 2019 | 26 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 5129 | 0.160 |
Why?
|
| Mice | 9 | 2024 | 10300 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 706 | 0.150 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 228 | 0.150 |
Why?
|
| Wilms Tumor | 1 | 2018 | 3 | 0.150 |
Why?
|
| Infratentorial Neoplasms | 1 | 2018 | 4 | 0.150 |
Why?
|
| Radiometry | 1 | 2018 | 35 | 0.150 |
Why?
|
| Middle Aged | 12 | 2021 | 16335 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2024 | 2901 | 0.150 |
Why?
|
| Brain Stem | 1 | 2018 | 28 | 0.150 |
Why?
|
| Combined Modality Therapy | 7 | 2018 | 354 | 0.150 |
Why?
|
| Oligopeptides | 1 | 2018 | 128 | 0.150 |
Why?
|
| Societies, Scientific | 1 | 2017 | 32 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 183 | 0.140 |
Why?
|
| Cyclophosphamide | 5 | 2020 | 75 | 0.140 |
Why?
|
| Skin | 3 | 2018 | 357 | 0.140 |
Why?
|
| Mammaplasty | 2 | 2016 | 43 | 0.140 |
Why?
|
| Vincristine | 4 | 2020 | 25 | 0.130 |
Why?
|
| Transfection | 1 | 2018 | 675 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 559 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 6 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 527 | 0.130 |
Why?
|
| Beta Particles | 1 | 2016 | 2 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 836 | 0.130 |
Why?
|
| Information Management | 1 | 2015 | 11 | 0.130 |
Why?
|
| Mastectomy | 2 | 2014 | 52 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2051 | 0.120 |
Why?
|
| Etoposide | 4 | 2018 | 33 | 0.120 |
Why?
|
| Meningioma | 1 | 2015 | 59 | 0.120 |
Why?
|
| Oxygen | 2 | 2016 | 313 | 0.120 |
Why?
|
| RNA Interference | 1 | 2018 | 590 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2013 | 259 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 693 | 0.120 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 2 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2015 | 102 | 0.110 |
Why?
|
| Animals | 9 | 2024 | 19662 | 0.110 |
Why?
|
| Global Health | 1 | 2015 | 167 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2021 | 6081 | 0.110 |
Why?
|
| Data Collection | 1 | 2015 | 372 | 0.110 |
Why?
|
| Osteolysis | 1 | 2014 | 17 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 40 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 130 | 0.110 |
Why?
|
| Prednisone | 3 | 2020 | 85 | 0.110 |
Why?
|
| Integrin beta1 | 1 | 2013 | 28 | 0.110 |
Why?
|
| Rhabdomyosarcoma | 2 | 2004 | 16 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 108 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 365 | 0.100 |
Why?
|
| Credentialing | 1 | 2012 | 15 | 0.100 |
Why?
|
| Thalidomide | 1 | 2012 | 32 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 330 | 0.090 |
Why?
|
| Infant | 5 | 2018 | 1493 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 66 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2008 | 52 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1028 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2012 | 67 | 0.090 |
Why?
|
| Bleomycin | 3 | 2018 | 32 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 195 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2020 | 5287 | 0.090 |
Why?
|
| Fluorouracil | 3 | 2017 | 56 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 58 | 0.090 |
Why?
|
| HIV Infections | 1 | 2016 | 913 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 678 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2022 | 228 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2012 | 90 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 2053 | 0.080 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2010 | 142 | 0.080 |
Why?
|
| Brain | 1 | 2017 | 1488 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 170 | 0.080 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 15 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1097 | 0.080 |
Why?
|
| Cytarabine | 3 | 2018 | 32 | 0.080 |
Why?
|
| Fibronectins | 1 | 2008 | 43 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 556 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2008 | 206 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 296 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 801 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1560 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2024 | 278 | 0.070 |
Why?
|
| Cetuximab | 2 | 2017 | 6 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 331 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 79 | 0.070 |
Why?
|
| Remission Induction | 3 | 2014 | 137 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2010 | 942 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2004 | 300 | 0.060 |
Why?
|
| Dexamethasone | 2 | 2018 | 201 | 0.060 |
Why?
|
| Mice, Hairless | 2 | 2016 | 17 | 0.060 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 115 | 0.060 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 13 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2018 | 1286 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 70 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 87 | 0.060 |
Why?
|
| Fibrosis | 2 | 2016 | 153 | 0.060 |
Why?
|
| Recurrence | 2 | 2018 | 603 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 915 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 116 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 474 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 1 | 2002 | 37 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 186 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 54 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 44 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 3621 | 0.050 |
Why?
|
| Massachusetts | 2 | 2018 | 2022 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 148 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 935 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2010 | 554 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 80 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 24 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2016 | 1997 | 0.040 |
Why?
|
| Neuropilins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 20 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2019 | 25 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 328 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 148 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1505 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 461 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 54 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2018 | 5 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 3 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 7 | 0.040 |
Why?
|
| Extremities | 1 | 2018 | 44 | 0.040 |
Why?
|
| Photons | 1 | 2018 | 25 | 0.040 |
Why?
|
| Florida | 1 | 2018 | 42 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 88 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 55 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2018 | 11 | 0.040 |
Why?
|
| Uncertainty | 1 | 2018 | 33 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 179 | 0.040 |
Why?
|
| Salvage Therapy | 2 | 2012 | 71 | 0.040 |
Why?
|
| SEER Program | 1 | 2018 | 66 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2018 | 44 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2018 | 38 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2018 | 48 | 0.040 |
Why?
|
| Leukemia | 1 | 2018 | 57 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 465 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 38 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 71 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 52 | 0.040 |
Why?
|
| Necrosis | 1 | 2018 | 140 | 0.040 |
Why?
|
| DNA Repair | 1 | 2019 | 242 | 0.040 |
Why?
|
| Wound Healing | 1 | 2018 | 174 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2017 | 20 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 108 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 411 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 526 | 0.030 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 674 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 42 | 0.030 |
Why?
|
| Skin Ulcer | 1 | 2016 | 14 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 217 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 8 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 21 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1119 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 194 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 21 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 79 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 115 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 742 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 101 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 4990 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 24 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 150 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 57 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 645 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 111 | 0.030 |
Why?
|
| Software | 1 | 2017 | 366 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2014 | 40 | 0.030 |
Why?
|
| Postmenopause | 1 | 2015 | 224 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 851 | 0.030 |
Why?
|
| Breast | 1 | 2016 | 174 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 410 | 0.030 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Pain Management | 1 | 2015 | 146 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 53 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 59 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2517 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 283 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 266 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 210 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 103 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 223 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 933 | 0.030 |
Why?
|
| Razoxane | 1 | 2012 | 2 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2015 | 256 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 805 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 513 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2014 | 202 | 0.030 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2012 | 2 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 801 | 0.020 |
Why?
|
| Carboplatin | 1 | 2012 | 40 | 0.020 |
Why?
|
| Metribolone | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 8 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 9 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 64 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 141 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2012 | 69 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 1471 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 284 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 103 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 2002 | 126 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 396 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1138 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2010 | 17 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1206 | 0.020 |
Why?
|
| Carmustine | 1 | 2009 | 10 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 144 | 0.020 |
Why?
|
| Internationality | 1 | 2009 | 43 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 74 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 39 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 147 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 61 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 885 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2376 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 1926 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 591 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 263 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2008 | 59 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 858 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 903 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 75 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2004 | 45 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 112 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 133 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 185 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 39 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2002 | 70 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2002 | 98 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2002 | 44 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 275 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 76 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 290 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 248 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1239 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2002 | 187 | 0.010 |
Why?
|